Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04414163
PHASE2

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Sponsor: ImmuneOncia Therapeutics Inc.

View on ClinicalTrials.gov

Summary

This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

Official title: An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

23

Start Date

2020-10-27

Completion Date

2026-02-28

Last Updated

2025-06-18

Healthy Volunteers

No

Interventions

DRUG

IMC-001

Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)

Locations (5)

Chonnam National University Hwasun Hospital

Gwangju, South Korea

Asan Medical Center

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Ulsan University Hospital

Ulsan, South Korea